Logo


AstraZeneca Pharma tanks 13% as parent firm halts Covid-19 vaccine trials

The company, which is formulating and testing the vaccine in collaboration with Oxford University, is among the front-runners for last-stage trials of potential virus vaccine

Covid vaccine
The development came after a volunteer showed signs of

Shares of AstraZeneca Pharma tanked as much as 13.4 per cent to hit a low of Rs 3,650 on the BSE on Wednesday after the company's parent firm abruptly paused global trials of its Covid-19 vaccine candidate. The development came after a volunteer showed signs of "potentially unexplained" illness. In a statement issued on Tuesday evening, the company said its "standard review process triggered a pause to vaccination to allow review of safety data". AstraZeneca Plc didn't reveal any information about the possible side effect except to call it "a ...